# Avenue Therapeutics (ATXI) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ATXI
## Company Profile
- Ticker: ATXI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.57 USD
- Market cap: Not available USD
- Last updated: 2026-09-02
## Business Overview
Avenue Therapeutics is a specialty pharmaceutical company focused on acute and hospital-based pain management. Its story revolves around trying to bring differentiated pain treatments into controlled clinical settings.
## Why The Stock Is Moving

Current closing-price context is not available for ATXI.

## Geographic Base

Avenue Therapeutics is headquartered in the United States and listed on NASDAQ. It sits in specialty pharma and acute-care pain management.

## Business Model

The company depends on clinical and regulatory progress, commercial strategy, and the ability to sustain a narrow product focus. Investors track trial updates, development milestones, and capital runway.

## Landscape Position

Avenue occupies a small acute-pain niche within specialty pharma. The stock tends to move on regulatory news and the market's view of the company’s ability to commercialize in a difficult category.

## Future Catalysts

- Avenue Therapeutics is largely a legacy and closeout story now, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event. The market is mainly focused on residual value.

## Recent News
- 2026-02-23 13:00 EST — [Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease](https://biopharmsignal.com/news/ATXI/avenue-therapeutics-enters-into-exclusive-worldwide-license-agreement-for-atx-04-a4f2b121) — Source: Avenue Therapeutics
- 2025-11-06 12:00 EST — [Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics](https://biopharmsignal.com/news/ATXI/avenue-therapeutics-announces-acquisition-of-subsidiary-baergic-bio-by-axsome-therapeutics) — Source: Avenue Therapeutics
- 2024-11-14 21:05 EST — [Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/ATXI/avenue-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights) — Source: Avenue Therapeutics
- 2024-10-09 12:30 EST — [Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit](https://biopharmsignal.com/news/ATXI/avenue-therapeutics-to-participate-in-maxim-group-s-2024-healthcare-virtual-summit) — Source: Avenue Therapeutics
- 2024-09-03 12:30 EST — [Avenue Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ATXI/avenue-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Avenue Therapeutics